The changing treatment of metastatic her2‑positive breast cancer (Review)
- Authors:
- Maria Mitsogianni
- Ioannis P. Trontzas
- Georgia Gomatou
- Stephanie Ioannou
- Nikolaos K. Syrigos
- Elias A. Kotteas
-
Affiliations: Oncology Unit, ‘Sotiria’ General Hospital, Athens School of Medicine, Athens 11527, Greece - Published online on: February 12, 2021 https://doi.org/10.3892/ol.2021.12548
- Article Number: 287
This article is mentioned in:
Abstract
 |
|
Torre LA, Islami F, Siegel RL, Ward EM and Jemal A: Global cancer in women: Burden and trends. Cancer Epidemiol Biomarkers Prev. 26:444–457. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A and McGuire WL: Human breast cancer: Correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science. 235:177–182. 1987. View Article : Google Scholar : PubMed/NCBI | |
|
Burstein HJ: The distinctive nature of HER2-positive breast cancers. N Engl J Med. 353:1652–1654. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Kennecke H, Yerushalmi R, Woods R, Cheang MC, Voduc D, Speers CH, Nielsen TO and Gelmon K: Metastatic behavior of breast cancer subtypes. J Clin Oncol. 28:3271–3277. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Harbeck N, Penault-Llorca F, Cortes J, Gnant M, Houssami N, Poortmans P, Ruddy K, Tsang J and Cardoso F: Breast cancer. Nat Rev Dis Primers. 5:662019. View Article : Google Scholar : PubMed/NCBI | |
|
Iqbal N and Iqbal N: Human epidermal growth factor receptor 2 (HER2) in cancers: Overexpression and therapeutic implications. Mol Biol Int. 2014:8527482014. View Article : Google Scholar : PubMed/NCBI | |
|
Mendes D, Alves C, Afonso N, Cardoso F, Passos-Coelho JL, Costa L, Andrade S and Batel-Marques F: The benefit of HER2-targeted therapies on overall survival of patients with metastatic HER2-positive breast cancer - a systematic review. Breast Cancer Res. 17:1402015. View Article : Google Scholar : PubMed/NCBI | |
|
Hudis CA: Trastuzumab - mechanism of action and use in clinical practice. N Engl J Med. 357:39–51. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Vogel CL, Cobleigh MA, Tripathy D, Gutheil JC, Harris LN, Fehrenbacher L, Slamon DJ, Murphy M, Novotny WF, Burchmore M, et al: Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol. 20:719–726. 2002. View Article : Google Scholar : PubMed/NCBI | |
|
Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, Fleming T, Eiermann W, Wolter J, Pegram M, et al: Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 344:783–792. 2001. View Article : Google Scholar : PubMed/NCBI | |
|
Andersson M, Lidbrink E, Bjerre K, Wist E, Enevoldsen K, Jensen AB, Karlsson P, Tange UB, Sørensen PG, Møller S, et al: Phase III randomized study comparing docetaxel plus trastuzumab with vinorelbine plus trastuzumab as first-line therapy of metastatic or locally advanced human epidermal growth factor receptor 2-positive breast cancer: The HERNATA study. J Clin Oncol. 29:264–271. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Robert N, Leyland-Jones B, Asmar L, Belt R, Ilegbodu D, Loesch D, Raju R, Valentine E, Sayre R, Cobleigh M, et al: Randomized phase III study of trastuzumab, paclitaxel, and carboplatin compared with trastuzumab and paclitaxel in women with HER-2-overexpressing metastatic breast cancer. J Clin Oncol. 24:2786–2792. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Valero V, Forbes J, Pegram MD, Pienkowski T, Eiermann W, von Minckwitz G, Roche H, Martin M, Crown J, Mackey JR, et al: Multicenter phase III randomized trial comparing docetaxel and trastuzumab with docetaxel, carboplatin, and trastuzumab as first-line chemotherapy for patients with HER2-gene-amplified metastatic breast cancer (BCIRG 007 study): Two highly active therapeutic regimens. J Clin Oncol. 29:149–156. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Baselga J, Manikhas A, Cortés J, Llombart A, Roman L, SemiglazovV F, Byakhov M, Lokanatha D, Forenza S, Goldfarb RH, et al: Phase III trial of nonpegylated liposomal doxorubicin in combination with trastuzumab and paclitaxel in HER2-positive metastatic breast cancer. Ann Oncol. 25:592–598. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Hamberg P, Bos MM, Braun HJ, Stouthard JM, van Deijk GA, Erdkamp FL, van der Stelt-Frissen IN, Bontenbal M, Creemers GJ, Portielje JE, et al Dutch Breast Cancer Trialists' Group (BOOG), : Randomized phase II study comparing efficacy and safety of combination-therapy trastuzumab and docetaxel vs. sequential therapy of trastuzumab followed by docetaxel alone at progression as first-line chemotherapy in patients with HER2+ metastatic breast cancer: HERTAX trial. Clin Breast Cancer. 11:103–113. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Inoue K, Nakagami K, Mizutani M, Hozumi Y, Fujiwara Y, Masuda N, Tsukamoto F, Saito M, Miura S, Eguchi K, et al: Randomized phase III trial of trastuzumab monotherapy followed by trastuzumab plus docetaxel versus trastuzumab plus docetaxel as first-line therapy in patients with HER2-positive metastatic breast cancer: The JO17360 Trial Group. Breast Cancer Res Treat. 119:127–136. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Pagani O, Klingbiel D, Ruhstaller T, Nolè F, Eppenberger S, Oehlschlegel C, Bernhard J, Brauchli P, Hess D, Mamot C, et al Swiss Group for Clinical Cancer Research (SAKK), : Do all patients with advanced HER2 positive breast cancer need upfront-chemo when receiving trastuzumab? Randomized III trial SAKK 22/99. Ann Oncol. 28:305–312. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Baselga J, Cortés J, Kim SB, Im SA, Hegg R, Im YH, Roman L, Pedrini JL, Pienkowski T, Knott A, et al CLEOPATRA Study Group, : Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N Engl J Med. 366:109–119. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Swain SM, Baselga J, Kim S-B, Ro J, Semiglazov V, Campone M, Ciruelos E, Ferrero JM, Schneeweiss A, Heeson S, et al CLEOPATRA Study Group, : Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer. N Engl J Med. 372:724–734. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Swain SM, Miles D, Kim SB, Im YH, Im SA, Semiglazov V, Ciruelos E, Schneeweiss A, Loi S, Monturus E, et al: Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study. Lancet Oncol. 21:519–530. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Miles D, Im YH, Fung A, Yoo B, Knott A, Heeson S, Beattie MS and Swain SM: Effect of docetaxel duration on clinical outcomes: Exploratory analysis of CLEOPATRA, a phase III randomized controlled trial. Ann Oncol. 28:2761–2767. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Bachelot T, Ciruelos E, Schneeweiss A, Puglisi F, Peretz-Yablonski T, Bondarenko I, Paluch-Shimon S, Wardley A, Merot JL, du Toit Y, et al PERUSE investigators, : Preliminary safety and efficacy of first-line pertuzumab combined with trastuzumab and taxane therapy for HER2-positive locally recurrent or metastatic breast cancer (PERUSE). Ann Oncol. 30:766–773. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Perez EA, López-Vega JM, Petit T, Zamagni C, Easton V, Kamber J, Restuccia E and Andersson M: Safety and efficacy of vinorelbine in combination with pertuzumab and trastuzumab for first-line treatment of patients with HER2-positive locally advanced or metastatic breast cancer: VELVET Cohort 1 final results. Breast Cancer Res. 18:1262016. View Article : Google Scholar : PubMed/NCBI | |
|
Inoue K, Ninomiya J, Saito T, Okubo K, Nakakuma T, Yamada H, Kimizuka K and Higuchi T; SBCCSG-36 investigators, : Eribulin, trastuzumab, and pertuzumab as first-line therapy for patients with HER2-positive metastatic breast cancer: A phase II, multicenter, collaborative, open-label, single-arm clinical trial. Invest New Drugs. 37:538–547. 2019.Erratum in: Invest New Drugs 37: 592–593, 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Urruticoechea A, Rizwanullah M, Im SA, Ruiz ACS, Láng I, Tomasello G, Douthwaite H, Badovinac Crnjevic T, Heeson S, Eng-Wong J, et al: Randomized phase III trial of trastuzumab plus capecitabine with or without pertuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer who experienced disease progression during or after trastuzumab-based therapy. J Clin Oncol. 35:3030–3038. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Urruticoechea A, Rizwanullah M, Im SA, Sánchez Ruiz AC, Lang I, Tomasello G, Douthwaite H, Badovinac Crnjevic T, Heeson S, Eng-Wong J, et al: Final overall survival (OS) analysis of PHEREXA: A randomized phase III trial of trastuzumab (H) + capecitabine (X) ± pertuzumab (P) in patients with HER2-positive metastatic breast cancer (MBC) who experienced disease progression during or after H-based therapy. J Clin Oncol. 36 (Suppl 15):10132018. View Article : Google Scholar | |
|
Lewis Phillips GD, Li G, Dugger DL, Crocker LM, Parsons KL, Mai E, Blättler WA, Lambert JM, Chari RV, Lutz RJ, et al: Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate. Cancer Res. 68:9280–9290. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Krop IE, Kim SB, González-Martín A, LoRusso PM, Ferrero JM, Smitt M, Yu R, Leung AC and Wildiers H; TH3RESA study collaborators, : Trastuzumab emtansine versus treatment of physician's choice for pretreated HER2-positive advanced breast cancer (TH3RESA): A randomised, open-label, phase 3 trial. Lancet Oncol. 15:689–699. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Krop IE, Kim SB, Martin AG, LoRusso PM, Ferrero JM, Badovinac-Crnjevic T, Hoersch S, Smitt M and Wildiers H: Trastuzumab emtansine versus treatment of physician's choice in patients with previously treated HER2-positive metastatic breast cancer (TH3RESA): Final overall survival results from a randomised open-label phase 3 trial. Lancet Oncol. 18:743–754. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Verma S, Miles D, Gianni L, Krop IE, Welslau M, Baselga J, Pegram M, Oh DY, Diéras V, Guardino E, et al EMILIA Study Group, : Trastuzumab emtansine for HER2-positive advanced breast cancer. N Engl J Med. 367:1783–1791. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Diéras V, Miles D, Verma S, Pegram M, Welslau M, Baselga J, Krop IE, Blackwell K, Hoersch S, Xu J, et al: Trastuzumab emtansine versus capecitabine plus lapatinib in patients with previously treated HER2-positive advanced breast cancer (EMILIA): A descriptive analysis of final overall survival results from a randomised, open-label, phase 3 trial. Lancet Oncol. 18:732–742. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Perez EA, Barrios C, Eiermann W, Toi M, Im YH, Conte P, Martin M, Pienkowski T, Pivot X, Burris H III, et al: Trastuzumab emtansine with or without pertuzumab versus trastuzumab plus taxane for human epidermal growth factor receptor 2-positive, advanced breast cancer: Primary results From the Phase III MARIANNE Study. J Clin Oncol. 35:141–148. 2017.Erratum in: J Clin Oncol 35: 2342, 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Perez EA, Barrios C, Eiermann W, Toi M, Im YH, Conte P, Martin M, Pienkowski T, Pivot XB, Burris HA III, et al: Trastuzumab emtansine with or without pertuzumab versus trastuzumab with taxane for human epidermal growth factor receptor 2-positive advanced breast cancer: Final results from MARIANNE. Cancer. 125:3974–3984. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Roskoski R Jr: Small molecule inhibitors targeting the EGFR/ErbB family of protein-tyrosine kinases in human cancers. Pharmacol Res. 139:395–411. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Cameron D, Casey M, Press M, Lindquist D, Pienkowski T, Romieu CG, Chan S, Jagiello-Gruszfeld A, Kaufman B, Crown J, et al: A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: Updated efficacy and biomarker analyses. Breast Cancer Res Treat. 112:533–543. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Gelmon KA, Boyle FM, Kaufman B, Huntsman DG, Manikhas A, Di Leo A, Martin M, Schwartzberg LS, Lemieux J, Aparicio S, et al: Lapatinib or trastuzumab plus taxane therapy for human epidermal growth factor receptor 2-positive advanced breast cancer: Final results of NCIC CTG MA.31. J Clin Oncol. 33:1574–1583. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Blackwell KL, Burstein HJ, Storniolo AM, Rugo HS, Sledge G, Aktan G, Ellis C, Florance A, Vukelja S, Bischoff J, et al: Overall survival benefit with lapatinib in combination with trastuzumab for patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: Final results from the EGF104900 Study. J Clin Oncol. 30:2585–2592. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Prat A and Baselga J: The role of hormonal therapy in the management of hormonal-receptor-positive breast cancer with co-expression of HER2. Nat Clin Pract Oncol. 5:531–542. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Montagna E and Colleoni M: Hormonal treatment combined with targeted therapies in endocrine-responsive and HER2-positive metastatic breast cancer. Ther Adv Med Oncol. 11:17588359198941052019. View Article : Google Scholar : PubMed/NCBI | |
|
Kaufman B, Mackey JR, Clemens MR, Bapsy PP, Vaid A, Wardley A, Tjulandin S, Jahn M, Lehle M, Feyereislova A, et al: Trastuzumab plus anastrozole versus anastrozole alone for the treatment of postmenopausal women with human epidermal growth factor receptor 2-positive, hormone receptor-positive metastatic breast cancer: Results from the randomized phase III TAnDEM study. J Clin Oncol. 27:5529–5537. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Johnston S, Pippen J Jr, Pivot X, Lichinitser M, Sadeghi S, Dieras V, Gomez HL, Romieu G, Manikhas A, Kennedy MJ, et al: Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer. J Clin Oncol. 27:5538–5546. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Huober J, Fasching PA, Barsoum M, Petruzelka L, Wallwiener D, Thomssen C, Reimer T, Paepke S, Azim HA, Ragosch V, et al: Higher efficacy of letrozole in combination with trastuzumab compared to letrozole monotherapy as first-line treatment in patients with HER2-positive, hormone-receptor-positive metastatic breast cancer - results of the eLEcTRA trial. Breast. 21:27–33. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Rimawi M, Ferrero J-M, de la Haba-Rodriguez J, Poole C, De Placido S, Osborne CK, Hegg R, Easton V, Wohlfarth C and Arpino G; PERTAIN Study Group, : First-line trastuzumab plus an aromatase inhibitor, with or without pertuzumab, in human epidermal growth factor receptor 2-positive and hormone receptor-positive metastatic or locally advanced breast cancer (PERTAIN): A randomized, open-label phase II trial. J Clin Oncol. 36:2826–2835. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Johnston SRD, Hegg R, Im SA, Park IH, Burdaeva O, Kurteva G, Press MF, Tjulandin S, Iwata H, Simon SD, et al: Phase III, randomized study of dual human epidermal growth factor receptor 2 (HER2) blockade with lapatinib plus trastuzumab in combination with an aromatase inhibitor in postmenopausal women with HER2-positive, hormone receptor-positive metastatic breast cancer: ALTERNATIVE. J Clin Oncol. 36:741–748. 2018.Retraction in: J Clin Oncol 39: 95, 2021. View Article : Google Scholar : PubMed/NCBI | |
|
Saura C, Oliveira M, Feng Y, Dai M-S, Hurvitz SA, Kim SB, Moy B, Delaloge S, Gradishar WJ, Masuda N, et al: Neratinib plus capecitabine versus lapatinib plus capecitabine in HER2-positive metastatic breast cancer previously treated with ≥2 HER2-directed regimens: Phase III NALA trial. J Clin Oncol. 38:3138–3149. 2019. View Article : Google Scholar | |
|
Awada A, Colomer R, Inoue K, Bondarenko I, Badwe RA, Demetriou G, Lee SC, Mehta AO, Kim SB, Bachelot T, et al: Neratinib plus paclitaxel vs trastuzumab plus paclitaxel in previously untreated metastatic ERBB2-positive breast cancer. The NEfERT-T randomized clinical trial. JAMA Oncol. 2:1557–1564. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Freedman RA, Gelman RS, Wefel JS, Melisko ME, Hess KR, Connolly RM, Van Poznak CH, Niravath PA, Puhalla SL, Ibrahim N, et al: Translational Breast Cancer Research Consortium (TBCRC) 022: A phase II trial of neratinib for patients with human epidermal growth factor receptor 2-positive breast cancer and brain metastases. J Clin Oncol. 34:945–952. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Freedman RA, Gelman RS, Anders CK, Melisko ME, Parsons HA, Cropp AM, Silvestri K, Cotter CM, Componeschi KP, Marte JM, et al Translational Breast Cancer Research Consortium, : TBCRC 022: A phase II trial of neratinib and capecitabine for patients with human epidermal growth factor receptor 2-positive breast cancer and brain metastases. J Clin Oncol. 37:1081–1089. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Ma F, Ouyang Q, Li W, Jiang Z, Tong Z, Liu Y, Li H, Yu S, Feng J, Wang S, et al: Pyrotinib or lapatinib combined with capecitabine in HER2-positive metastatic breast cancer with prior taxanes, anthracyclines, and/or trastuzumab: A randomized, phase II study. J Clin Oncol. 37:2610–2619. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Xu B, Yan M, Ma F, Hu XC, Feng FJ, Ouyang Q, Tong Z, Li H, Zhang Q, Sun T, et al: Pyrotinib or lapatinib plus capecitabine for HER2+ metastatic breast cancer (PHOEBE): a randomized phase III trial. J Clin Oncol. 38 (Suppl 15):10032020. View Article : Google Scholar : PubMed/NCBI | |
|
Jiang Z, Yan M, Hu X, Zhang Q, Ouyang Q, Feng J, Yin Y, Sun T, Tong Z, Wang X, et al: Pyrotinib combined with capecitabine in women with HER2+ metastatic breast cancer previously treated with trastuzumab and taxanes: A randomized phase III study. J Clin Oncol. 37 (Suppl 15):10012019. View Article : Google Scholar : PubMed/NCBI | |
|
Blair HA: Pyrotinib: First global approval. Drugs. 78:1751–1755. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Murthy RK, Loi S, Okines A, Paplomata E, Hamilton E, Hurvitz SA, Lin NU, Borges V, Abramson V, Anders C, et al: Tucatinib, trastuzumab and capecitabine for HER2-positive metastatic breast cancer. N Engl J Med. 382:597–609. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Lin NU, Borges V, Anders C, Murthy RK, Paplomata E, Hamilton E, Hurvitz S, Loi S, Okines A, Abramson V, et al: Intracranial efficacy and survival with tucatinib plus trastuzumab and capecitabine for previously treated HER2-positive breast cancer with brain metastases in the HER2CLIMB trial. J Clin Oncol. 38:2610–2619. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Modi S, Saura C, Yamashita T, Park YH, Kim SB, Tamura K, Andre F, Iwata H, Ito Y, Tsurutani J, et al DESTINY-Breast01 Investigators, : Trastuzumab Deruxtecan in previously treated HER2-positive breast cancer. N Engl J Med. 382:610–621. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Jerusalem G, Park YH, Yamashita T, Hurvitz SA, Chen S, Cathcart J, Lee C and Perrin C: CNS metastases in HER2-positive metastatic breast cancer treated with trastuzumab deruxtecan: DESTINY-Breast01 subgroup analyses. Ann Oncol. 31:Abstract nr. 1380. 2020. View Article : Google Scholar | |
|
Banerji U, van Herpen CML, Saura C, Thistlethwaite F, Lord S, Moreno V, Macpherson IR, Boni V, Rolfo C, de Vries EGE, et al: Trastuzumab duocarmazine in locally advanced and metastatic solid tumours and HER2-expressing breast cancer: A phase 1 dose-escalation and dose-expansion study. Lancet Oncol. 20:1124–1135. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Rinnerthaler G, Gampenrieder SP and Greil R: HER2 directed antibody-drug-conjugates beyond T-DM1 in breast cancer. Int J Mol Sci. 20:1152019. View Article : Google Scholar | |
|
Dolcetti R: Predictive value of FcR polymorphisms. A further step on the long and winding road to application. JAMA Oncol. 3:342–343. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Rugo HS, Im SA, Cardoso F, Cortes J, Curigliano G, Pegram MD, Musolino A, Bachelot T, Wright GS, De Laurentiis M, et al: Phase III SOPHIA study of margetuximab + chemotherapy vs trastuzumab + chemotherapy in patients with HER2+ metastatic breast cancer after prior anti-HER2 therapies: second interim overall survival analysis. Cancer Res. 80:Abstract Nr. GS1-02. 2019. | |
|
Meric-Bernstam F, Hanna D, Beeram M, Lee K, Kang Y, Chaves J, Lee J, Goodwin R, Vaklavas C, Oh D, et al: Safety, anti-tumor activity, and biomarker results of the HER2-targeted bispecific antibody ZW25 in HER2-expressing solid tumors. Ann Oncol. 30 (Suppl 5):v159–v193. 2019. View Article : Google Scholar | |
|
Alsina M, Boni V, Schellens J, Moreno V, Bol K, Westendorp M, Sirulnik LA, Tabernero J and Calvo E: First-in-human phase 1/2 study of MCLA-128, a full length IgG1 bispecific antibody targeting HER2 and HER3: Final phase 1 data and preliminary activity in HER2+ metastatic breast cancer (MBC). J Clin Oncol. 35 (Suppl 15):25222017. View Article : Google Scholar | |
|
Schettini F, Giudici F, Giuliano M, Cristofanilli M, Arpino G, Del Mastro L, Puglisi F, De Placido S, Paris I, De Placido P, et al: Overal survival of CDK4/6-inhibitors-based treatments in clinically relevant subgroups of metastatic breast cancer: Systematic review and meta-analysis. J Natl Cancer Inst. 112:1089–1097. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Tolaney SM, Wardley AM, Zambelli S, Hilton JF, Troso-Sandoval TA, Ricci F, Im SA, Kim SB, Johnston SR, Chan A, et al: Abemaciclib plus trastuzumab with or without fulvestrant versus trastuzumab plus standard-of-care chemotherapy in women with hormone receptor-positive, HER2-positive advanced breast cancer (monarcHER): A randomised, open-label, phase 2 trial. Lancet Oncol. 21:763–775. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Ciruelos E, Villagrasa P, Paré L, Oliveira M, Pernas S, Cortés J, Soberino J, Adamo B, Vazquez S, Martínez N, et al: SOLTI-1303 PATRICIA phase II trial (STAGE 1) - Palbociclib and trastuzumab in postmenopausal patients with HER2-positive metastatic breast cancer. Cancer Res. 79 (Suppl 4):Abstract nr PD3-03. 2019. | |
|
Metzger O, Mandrekar S, Loibl S, Mundhenke C, Seiler S, Valagussa P, Lim E, Tripathy D, Winer EP, Huang C, et al: PATINA: A randomized, open label, phase III trial to evaluate the efficacy and safety of palbociclib + anti-HER2 therapy + endocrine therapy (ET) vs. anti-HER2 therapy + ET after induction treatment for hormone receptor positive (HR+)/HER2-positive metastatic breast cancer (MBC). Cancer Res. 79 (Suppl 4):Abstract nr OT3-02-07. 2019. | |
|
Wang Q, Liu P, Spangle JM, Von T, Roberts TM, Lin NU, Krop IE, Winer EP and Zhao JJ: PI3K-p110α mediates resistance to HER2-targeted therapy in HER2+, PTEN-deficient breast cancers. Oncogene. 35:3607–3612. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Mezni E, Vicier C, Guerin M, Sabatier R, Bertucci F and Gonçalves A: New therapeutics in HER2-positive advanced breast cancer: Towards a change in clinical practices? Cancers (Basel). 12:15732020. View Article : Google Scholar | |
|
André F, O'Regan R, Ozguroglu M, Toi M, Xu B, Jerusalem G, Masuda N, Wilks S, Arena F, Isaacs C, et al: Everolimus for women with trastuzumab-resistant, HER2-positive, advanced breast cancer (BOLERO-3): A randomised, double-blind, placebo-controlled phase 3 trial. Lancet Oncol. 15:580–591. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Hurvitz SA, André F, Jiang Z, Shao Z, Mano MS, Neciosup SP, Tseng LM, Zhang Q, Shen K, Liu D, et al: Combination of everolimus with trastuzumab plus paclitaxel as first-line treatment for patients with HER2-positive advanced breast cancer (BOLERO-1): A phase 3, randomised, double-blind, multicentre trial. Lancet Oncol. 16:816–829. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
André F, Hurvitz S, Fasolo A, Tseng LM, Jerusalem G, Wilks S, O'Regan R, Isaacs C, Toi M, Burris H, et al: Molecular alterations and everolimus efficacy in human epidermal growth factor receptor 2-overexpressing metastatic breast cancers: Combined exploratory biomarker analysis From BOLERO-1 and BOLERO-3. J Clin Oncol. 34:2115–2124. 2016.Erratum in: J Clin Oncol 37: 357, 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Guerin M, Rezai K, Isambert N, Campone M, Autret A, Pakradouni J, Provansal M, Camerlo J, Sabatier R, Bertucci F, et al: PIKHER2: A phase IB study evaluating buparlisib in combination with lapatinib in trastuzumab-resistant HER2-positive advanced breast cancer. Eur J Cancer. 86:28–36. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Jain S, Shah AN, Santa-Maria CA, Siziopikou K, Rademaker A, Helenowski I, Cristofanilli M and Gradishar WJ: Phase I study of alpelisib (BYL-719) and trastuzumab emtansine (T-DM1) in HER2-positive metastatic breast cancer (MBC) after trastuzumab and taxane therapy. Breast Cancer Res Treat. 171:371–381. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Viale G, Morganti S, Ferraro E, Zagami P, Marra A and Curigliano G: What therapies are on the horizon for HER2 positive breast cancer? Expert Rev Anticancer Ther. 19:811–822. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Emens LA, Esteva F, Beresford M, Saura C, De Laurentiis M, Kim SB, Im SA, Patre M, Wang Y, Mani A, et al: Results from KATE2, a randomized phase 2 study of atezolizumab (atezo)+trastuzumab emtasine (T-DM1) vs placebo (pbo)+T-DM1 in previously treated HER2+ advanced breast cancer (BC). Cancer Res. 79 (Suppl 4):Abstract nr PD3-01. 2019. | |
|
Emens L, Esteva F, Beresford M, Saura C, De Laurentiis M, Kim SB, Im SA, Wang Y, Mani A, Shah J, et al: Overall survival (OS) in KATE2, a phase 2 study of programmed death ligand 1 (PD-L1) inhibitor atezolizumab (atezo)+trastuzumab emtasine (T-DM1) vs placebo (pbo)+T-DM1 in previously treated HER2+ advanced breast cancer (BC). Ann Oncol. 30 (Suppl 5):v104–v142. 2019. View Article : Google Scholar | |
|
Loi S, Giobbie-Hurder A, Gombos A, Bachelot T, Hui R, Curigliano G, Campone M, Biganzoli L, Bonnefoi H, Jerusalem G, et al International Breast Cancer Study Group and the Breast International Group, : Pembrolizumab plus trastuzumab in trastuzumab-resistant, advanced, HER2-positive breast cancer (PANACEA): A single-arm, multicentre, phase 1b-2 trial. Lancet Oncol. 20:371–382. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Ayoub NM, Al-Shami KM and Yaghan RJ: Immunotherapy for HER2-positive breast cancer: Recent advances and combination therapeutic approaches. Breast Cancer (Dove Med Press). 11:53–69. 2019.PubMed/NCBI |
